New Delhi: A Mumbai-based health-tech start-up has launched an application for Indian citizens to book an appointment with the nearest doctor or the vaccination clinic to get themselves vaccinated. This comes at a time when the country is waiting for the coronavirus vaccine with bated breath.
WONDRx is a made-in-India health-tech start-up working on Digital India mandate augmenting ‘AtmaNirbhar’ concept across the healthcare stakeholders in the country.
Bringing in much needed convenience and transparency, this platform will ensure vaccination reaches every nook and corner of India. The health-tech firm, WONDRx, has tied up with doctors and qualified healthcare service providers across the country to ensure easy accessibility of the vaccine to the concerned citizens through an app.
WONDRx has already curated and listed 180,000-plus healthcare providers on its WONDRx consumer app, making it the largest healthcare providers’ aggregator in India.
Speaking on the occasion, co-founder and Director of WONDRx, Pankaj Agarwal said, “Our app would list the details of all vaccination clinics that we are curating, along with the fees to be paid for availing the vaccination at a pre-booked time slot.”
He added, “Vaccination booking via pre-booked slots will ensure crowd management as well while maintaining social distancing aspects. People from every nook and corner of this country would be able to take an informed decision based on the details provided.”
Agarwal further said that the application would act as a bridge between the residents of each state and the vaccination clinics. This would help the people to schedule their appointment with the vaccination clinics of choice and do away with waiting in uncertainties and long queues.
The app would be compatible with Android phones in the first phase and iOS versions would be launched at later stages. This app would be available as a free download from Google Play Store for every consumer and healthcare provider of the country.
Dwelling on the advantages of this product, the founder and Director of WONDRx, Pankaj Sindhu, stated, “This product will make the vaccination journey highly convenient for every stakeholder — consumers, doctors, vaccine distributors and manufacturers — while ensuring required transparency and control around vaccination. It would give control and visibility right from the manufacturer to the end consumer at the last mile and ensure a controlled supply chain.”
[3:34 PM, 9/16/2020] Baibhav Mishra: I told you to sleep
[3:34 PM, 9/16/2020] Mohammed: Russia to supply 100 million doses of Sputnik V vaccine to Dr Reddy’s
New Delhi, Sep 16 (IANS) The Russian Direct Investment Fund (RDIF) and Dr Reddy’s Laboratories Limited, a global pharmaceutical company headquartered in India, have agreed to cooperate on clinical trials and distribution of Sputnik V Covid-19 vaccine in India, Russia’s sovereign wealth fund revealed in a statement on Wednesday.
Sputnik V, an adenovirus vector-based vaccine, was developed by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology, along with the Russian Direct Investment Fund and registered on August 11.
“On regulatory approval in India, RDIF shall supply to Dr Reddy’s 100 million doses of the vaccine. The Sputnik V vaccine, which is based on well-studied human adenoviral vector platform with proven safety, is undergoing clinical trials for the coronavirus pandemic,” said a statement from the fund.
The Russian Direct Investment Fund said that the deliveries could potentially begin in late 2020 subject to completion of successful trials and registration of the vaccine by regulatory authorities in India.
“The agreement between RDIF and Dr Reddy’s reflects the growing awareness of countries and organisations to have a diversified anti-COVID vaccine portfolio to protect their populations,” RDIF added.
Earlier this month, NITI Aayog member, Dr V.K. Paul, had said that the Russian government has sought India’s help in manufacturing the Sputnik V vaccine and also to conduct Phase-3 trials or bridging studies in the country.
Addressing a press conference on Tuesday, ICMR Director General Balram Bhargava also said, “Russia has a good history of vaccine manufacturing hence we assume that this vaccine is also good. There is a dialogue going on between the high-level committees of the governments of India and Russia. We are trying to work out its mechanism.”